The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Severson, Tesa M; Wolf, Denise M; Yau, Christina; Peeters, Justine; Wehkam, Diederik; Schouten, Philip C; Chin, Suet-Feung; Majewski, Ian J; Michaut, Magali; Bosma, Astrid; Pereira, Bernard; Bismeijer, Tycho; Wessels, Lodewyk; Caldas, Carlos; Bernards, René; Simon, Iris M; Glas, Annuska M; Linn, Sabine; van 't Veer, Laura

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Published version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/270220

Repository DOI

https://doi.org/10.17863/CAM.17063

Files

Published version (1.16 MB)

Type

Article

Authors

Severson, Tesa M

Wolf, Denise M

Yau, Christina

Peeters, Justine

Wehkam, Diederik

Show 5 more

Keywords

Humans, Breast Neoplasms, BRCA1 Protein, Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Cluster Analysis, Sensitivity and Specificity, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Female, Gene Regulatory Networks, Triple Negative Breast Neoplasms, Biomarkers, Tumor, Poly(ADP-ribose) Polymerase Inhibitors

Journal Title

Breast cancer research : BCR

Journal ISSN

1465-5411
1465-542X

Volume Title

19

Publisher DOI

https://doi.org/10.1186/s13058-017-0861-2

Rights

Attribution 4.0 International

Sponsorship

Department of Health (via National Institute for Health Research (NIHR)) (unknown)
European Commission FP7 Network of Excellence (NoE) (260791)
European Commission FP7 Collaborative projects (CP) (258967)
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0515-10090)
EC FP7 CP (258967)

Collections

Scholarly Works - Oncology